Literature DB >> 10438804

Tandemization of a subregion of the enhancer sequences from SRS 19-6 murine leukemia virus associated with T-lymphoid but not other leukemias.

S W Granger1, L M Bundy, H Fan.   

Abstract

Most simple retroviruses induce tumors of a single cell type when infected into susceptible hosts. The SRS 19-6 murine leukemia virus (MuLV), which originated in mainland China, induces leukemias of multiple cellular origins. Indeed, infected mice often harbor more than one tumor type. Since the enhancers of many MuLVs are major determinants of tumor specificity, we tested the role of the SRS 19-6 MuLV enhancers in its broad disease specificity. The enhancer elements of the Moloney MuLV (M-MuLV) were replaced by the 170-bp enhancers of SRS 19-6 MuLV, yielding the recombinants DeltaMo+SRS(+) and DeltaMo+SRS(-) M-MuLV. M-MuLV normally induces T-lymphoid tumors in all infected mice. Surprisingly, when neonatal mice were inoculated with DeltaMo+SRS(+) or DeltaMo+SRS(-) M-MuLV, all tumors were of T-lymphoid origin, typical of M-MuLV rather than SRS 19-6 MuLV. Thus, the SRS 19-6 MuLV enhancers did not confer the broad disease specificity of SRS 19-6 MuLV to M-MuLV. However, all tumors contained DeltaMo+SRS M-MuLV proviruses with common enhancer alterations. These alterations consisted of tandem multimerization of a subregion of the SRS 19-6 enhancers, encompassing the conserved LVb and core sites and adjacent sequences. Moreover, when tumors induced by the parental SRS 19-6 MuLV were analyzed, most of the T-lymphoid tumors had similar enhancer alterations in the same region whereas tumors of other lineages retained the parental SRS 19-6 MuLV enhancers. These results emphasize the importance of a subregion of the SRS 19-6 MuLV enhancer in induction of T-cell lymphoma. The relevant sequences were consistent with crucial sequences for T-cell lymphomagenesis identified for other MuLVs such as M-MuLV and SL3-3 MuLV. These results also suggest that other regions of the SRS 19-6 MuLV genome contribute to its broad leukemogenic spectrum.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10438804      PMCID: PMC104241     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Detection of specific sequences among DNA fragments separated by gel electrophoresis.

Authors:  E M Southern
Journal:  J Mol Biol       Date:  1975-11-05       Impact factor: 5.469

2.  Identification of an essential site for transcriptional activation within the human T-cell receptor delta enhancer.

Authors:  J M Redondo; J L Pfohl; M S Krangel
Journal:  Mol Cell Biol       Date:  1991-11       Impact factor: 4.272

3.  Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis.

Authors:  W S Hayward; B G Neel; S M Astrin
Journal:  Nature       Date:  1981-04-09       Impact factor: 49.962

4.  Non-function of a Moloney murine leukaemia virus regulatory sequence in F9 embryonal carcinoma cells.

Authors:  E Linney; B Davis; J Overhauser; E Chao; H Fan
Journal:  Nature       Date:  1984 Mar 29-Apr 4       Impact factor: 49.962

5.  Nuclear factor 1 activates the feline leukemia virus long terminal repeat but is posttranscriptionally down-regulated in leukemia cell lines.

Authors:  M Plumb; R Fulton; L Breimer; M Stewart; K Willison; J C Neil
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

6.  Determination of the leukaemogenicity of a murine retrovirus by sequences within the long terminal repeat.

Authors:  J Lenz; D Celander; R L Crowther; R Patarca; D W Perkins; W A Haseltine
Journal:  Nature       Date:  1984 Mar 29-Apr 4       Impact factor: 49.962

7.  A 3' end fragment encompassing the transcriptional enhancers of nondefective Friend virus confers erythroleukemogenicity on Moloney leukemia virus.

Authors:  P A Chatis; C A Holland; J E Silver; T N Frederickson; N Hopkins; J W Hartley
Journal:  J Virol       Date:  1984-10       Impact factor: 5.103

8.  Integrated Moloney murine leukemia virus DNA studied by using complementary DNA which does not recognize endogenous related sequences.

Authors:  L T Bacheler; H Fan
Journal:  J Virol       Date:  1980-03       Impact factor: 5.103

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Role for the 3' end of the genome in determining disease specificity of Friend and Moloney murine leukemia viruses.

Authors:  P A Chatis; C A Holland; J W Hartley; W P Rowe; N Hopkins
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

View more
  3 in total

1.  Control of pathogenicity and disease specificity of a T-lymphomagenic gammaretrovirus by E-box motifs but not by an overlapping glucocorticoid response element.

Authors:  Ditte Ejegod; Karina Dalsgaard Sørensen; Ilona Mossbrugger; Leticia Quintanilla-Martinez; Jörg Schmidt; Finn Skou Pedersen
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

2.  Novel insights into the pathogenesis of the Graffi murine leukemia retrovirus.

Authors:  Véronique Voisin; Corinne Barat; Trang Hoang; Eric Rassart
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

3.  Mutation of all Runx (AML1/core) sites in the enhancer of T-lymphomagenic SL3-3 murine leukemia virus unmasks a significant potential for myeloid leukemia induction and favors enhancer evolution toward induction of other disease patterns.

Authors:  Karina Dalsgaard Sørensen; Leticia Quintanilla-Martinez; Sandra Kunder; Jörg Schmidt; Finn Skou Pedersen
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.